Benitec Biopharma Inc.
BNTCNASDAQHealthcareBiotechnology

About Benitec Biopharma

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Company Information

CEOJerel Banks
Founded1995
Employees19
CountryUnited States
Fiscal YearJuly - June

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Phone510 780 0819
Address
3940 Trust Way Hayward, California 94545 United States

Corporate Identifiers

CIK0001552795
CUSIP08205P100
ISINUS08205P2092
SIC2834

Leadership Team & Key Executives

Dr. Jerel A. Banks M.D., Ph.D.
Executive Chairman and Chief Executive Officer
Megan Joan Boston B.Com., C.A.
Chief Financial Officer, Secretary and Director
Sophie Mukadam
Chief Operating Officer
Dr. Michael Graham
Head of Discovery and Founding Scientist
Dr. Claudia Kloth Ph.D.
Senior Vice President of Manufacturing